Correction: Is there a future for Akt inhibitors in the treatment of cancer? (Clinical Cancer Research (2019) 22 (2599–2601) Doi:10.1158/1078-0432.CCR-16-0100);Is there a future for AKT inhibitors in the treatment of cancer?

Clinical Cancer Research

Volumn 22, Issue 11, 2016, Pages 2599-2601

  Jansen, Valerie M ^a   Mayer, Ingrid A ^a   Arteaga, Carlos L ^a  

^a VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; ESTROGEN RECEPTOR; FUSED HETEROCYCLIC RINGS; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B;

BREAST TUMOR; FEMALE; HUMAN; POSTMENOPAUSE;

BREAST NEOPLASMS; FEMALE; HETEROCYCLIC COMPOUNDS, 3-RING; HUMANS; PHOSPHATIDYLINOSITOL 3-KINASES; POSTMENOPAUSE; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, ESTROGEN;

EID: 84971532172     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-18-4265     Document Type: Erratum

References (14)

1. MaCX, Sanchez C, Gao F, Crowder R, Naughton M, Pluard T, et al. A phase I study of the AKT inhibitor MK-2206 in combination with hormonal therapy in postmenopausal women with estrogen receptor-positive metastatic breast cancer. Clin Cancer Res 2016;22:2650-8.
2. Miller TW, Hennessy BT, Gonzalez-Angulo AM, Fox EM, Mills GB, Chen H, et al. Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer. J Clin Invest 2010;120:2406-13.
3. Bachelot T, Bourgier C, Cropet C, Ray-Coquard I, Ferrero JM, Freyer G, et al. Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: A GINECO study. J Clin Oncol 2012;30:2718-24.
4. Thorpe LM, Yuzugullu H, Zhao JJ. PI3K in cancer: Divergent roles of isoforms, modes of activation and therapeutic targeting. Nat Rev Cancer 2015;15:7-24.
5. Vivanco I, Chen ZC, Tanos B, Oldrini B, Hsieh WY, Yannuzzi N, et al. A kinase-independent function of AKT promotes cancer cell survival. Elife 2014;3.
6. Wu WI, Voegtli WC, Sturgis HL, Dizon FP, Vigers GPA, Brandhuber BJ. Crystal structure of human AKT1 with an allosteric inhibitor reveals a new mode of kinase inhibition. PLoS One 2010;5:e12913.
7. Parikh C, Janakiraman V, Wu WI, Foo CK, Kljavin NM, Chaudhuri S, et al. Disruption of PH-kinase domain interactions leads to oncogenic activation of AKT in human cancers. Proc Natl Acad Sci U S A 2012;109:19368-73.
8. Chandarlapaty S, Sawai A, Scaltriti M, Rodrik-Outmezguine V, Grbovic- Huezo O, Serra V, et al. AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. Cancer Cell 2011;19: 58-71.
9. Fox EM, Kuba MG, Miller TW, Davies BR, Arteaga CL. Autocrine IGF-I/insulin receptor axis compensates for inhibition of AKT in ER-positive breast cancer cellswith resistance to estrogen deprivation. Breast Cancer Res 2013;15:R55.
10. Baselga J, Ims A, Iwata H, Clemons M, Ito Y, Awada A, et al. PIK3CAstatus in circulating tumor DNA (ctDNA) predicts efficacy of buparlisib (BUP) plus fulvestrant (FULV) in postmenopausal women with endocrine-resistant HR/HER2- advanced breast cancer (BC): First results from the randomized, phase III BELLE-2 trial [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8- 12; San Antonio, TX. Philadelphia (PA): AACR. Abstract nr S6-01.
11. Baselga J, Campone M, Piccart M, Burris HA III, Rugo HS, Sahmoud T, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 2012;366:520-9.
12. Carpten JD, Faber AL, Horn C, Donoho GP, Briggs SL, Robbins CM, et al. A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature 2007;448:439-44.
13. Hyman D, Smyth L, Bedard PL, Oza A, Dean E, Armstrong A, et al. AZD5363, a catalytic pan-Akt inhibitor, in Akt1 E17K mutation positive advanced solid tumors [abstract]. In: Proceedings of the AACR-NCIEORTC International Conference: Molecular Targets and Cancer Therapeutics; 2015 Nov 5-9; Boston, MA. Philadelphia (PA): AACR. Abstract nr B109.
14. Conley BA, Doroshow JH. Molecular analysis for therapy choice: NCI MATCH. Semin Oncol 2014;41:297-9.